Compare
Omada Health, Inc. vs DocGo Inc. vs GeneDx Holdings Corp. vs Pennant Group, Inc.
| Latest fiscal year | Omada Health, Inc. OMDA | DocGo Inc. DCGO | GeneDx Holdings Corp. WGS | Pennant Group, Inc. PNTG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $260.21M | $322.20M | $427.54M | $947.71M |
| Revenue growth (YoY) | +53.2% | -47.7% | +40.0% | +36.3% |
| Gross margin | 65.7% | n/a | 69.7% | n/a |
| Operating margin | -4.6% | -55.3% | -3.1% | 5.5% |
| Net margin | -4.9% | -56.6% | -4.9% | 3.1% |
| Net income | -$12.78M | -$182.40M | -$21.02M | $29.58M |
| EPS (Diluted) | -$0.35 | -$1.84 | -$0.73 | $0.84 |
| Operating cash flow | $18.25M | $34.45M | $33.28M | $48.29M |
| Free cash flow | $16.93M | $29.91M | $14.26M | $36.26M |
| Cash & equivalents | $222.04M | $51.02M | $105.00M | n/a |
| Total assets | $305.41M | $217.10M | $523.71M | $968.18M |
| Total liabilities | $75.73M | $91.23M | $215.53M | $593.93M |
| Shareholders' equity | $229.68M | $144.01M | $308.18M | $374.25M |
| Return on year-end equity | -5.6% | -126.7% | -6.8% | 7.9% |
| Shares outstanding | 58.43M | 98.64M | 29.25M | 34.63M |
Revenue, most recent five fiscal years
| Fiscal year | Omada Health, Inc. | DocGo Inc. | GeneDx Holdings Corp. | Pennant Group, Inc. |
|---|---|---|---|---|
| Latest | $260.21M Ended 2025-12-31 | $322.20M Ended 2025-12-31 | $427.54M Ended 2025-12-31 | $947.71M Ended 2025-12-31 |
| 1 year earlier | $169.80M Ended 2024-12-31 | $616.56M Ended 2024-12-31 | $305.45M Ended 2024-12-31 | $695.24M Ended 2024-12-31 |
| 2 years earlier | $122.78M Ended 2023-12-31 | $624.29M Ended 2023-12-31 | $202.57M Ended 2023-12-31 | $544.89M Ended 2023-12-31 |
| 3 years earlier | n/a | $440.52M Ended 2022-12-31 | $234.69M Ended 2022-12-31 | $473.24M Ended 2022-12-31 |
| 4 years earlier | n/a | $318.72M Ended 2021-12-31 | $212.19M Ended 2021-12-31 | $439.69M Ended 2021-12-31 |